Transcatheter Tricuspid Valve Replacement System

The Structural Heart team at Powers Health continue to offer groundbreaking heart valve replacement procedures with the new, minimally invasive treatment option for patients with severe symptomatic tricuspid regurgitation (TR). In another milestone for cardiac care, the EVOQUE system is the world’s first transcatheter tricuspid valve replacement (TTVR) device, designed to improve the quality of life in these patients without the need for open heart surgery.

Tricuspid regurgitation is a life-threatening condition that affects an estimated 1.6 million Americans. The disease occurs when the tricuspid valve, located on the right side of the heart, cannot properly close letting blood flow backward into the atrium, forcing the heart to work harder to move blood to the body. Symptoms of the disease may include abnormal heart rhythms, fatigue, shortness of breath and swelling in the abdomen, legs and neck veins. If untreated, TR may lead to heart failure.

Designed with Patients in Mind

The EVOQUE device is threaded through the femoral vein to the heart and deployed in the valve, fully replacing the weakened area without removing the valve to eliminate the backflow of blood. Made with a self-expanding frame, the EVOQUE device is available in three sizes, allowing for an accurate fit. Patients who undergo the procedure experience faster recovery times and an improved quality of life.